Expanded Indications of Molecular-Targeted Drugs in Perioperative Therapy of Breast Cancer
Tokyo Women's Medical University Journal · 2024-06 · 8 · 1-9
DOI: 10.24488/twmuj.2024003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Tokyo Women's Medical University Journal, 2024-06. Verfasst von Eiichiro Noguchi und 1 weiteren Autor:innen.
Abstract (Originalsprache)
In recent years, numerous molecular-targeted drugs have become available for the perioperative therapy of breast cancer, bringing about a revolution in breast cancer treatment. Based on comprehensive gene expression analysis, breast cancer is classified into four subtypes, and there are limitations regarding the drugs that can be used depending on the subtype and the cancer progression. Therefore, it is necessary to identify and select the appropriate drugs for each subtype. This review explores the expanded indications of four recently available molecular-targeted drugs in breast cancer treatment.
Schlagwörter
Zitieren
APA
Noguchi, E., & Akashi-Tanaka, S. (2024). Expanded Indications of Molecular-Targeted Drugs in Perioperative Therapy of Breast Cancer. Tokyo Women's Medical University Journal, 8(0), 1-9. https://doi.org/10.24488/twmuj.2024003
Vancouver
Noguchi E, Akashi-Tanaka S. Expanded Indications of Molecular-Targeted Drugs in Perioperative Therapy of Breast Cancer. Tokyo Women's Medical University Journal. 2024;8(0):1-9. doi:10.24488/twmuj.2024003
BibTeX
@article{Noguchi2024,
author = {Noguchi, Eiichiro and Akashi-Tanaka, Sadako},
title = {Expanded Indications of Molecular-Targeted Drugs in Perioperative Therapy of Breast Cancer},
journal = {Tokyo Women's Medical University Journal},
year = {2024},
volume = {8},
number = {0},
pages = {1--9},
doi = {10.24488/twmuj.2024003}
}
EUVIMED